Your search for comorbidities returned 6 results

Semaglutide, a GLP-1 receptor agonist, is currently approved under 3 brand names: Ozempic, Rybelsus, and Wegovy.

A systematic review was conducted to study the association between idiopathic inflammatory myopathies and incidence of cardiovascular outcomes.

A study was conducted to determine sex differences in clinical outcomes following treatment with ticagrelor monotherapy after DAPT in patient with ACS.

Researchers examined the benefits of routine immunologic testing among children with severe bacterial infections.

Researchers sought to evaluate long-term efficacy, safety, and tolerability of fremanezumab among patients with high-frequency episodic migraine or chronic migraine who had a history of 3 or more therapeutic failures.

A greater proportion of patients who received oral semaglutide achieved superior weight loss after 68 weeks compared with those who received placebo.